Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NLNK

NewLink Genetics (NLNK) Stock Price, News & Analysis

NewLink Genetics logo

About NewLink Genetics Stock (NASDAQ:NLNK)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$14.10
52-Week Range
N/A
Volume
N/A
Average Volume
547,540 shs
Market Capitalization
$162.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NLNK Stock News Headlines

Reproduction DNA and Genetics
What Wall Street expects from NewLink Genetics's earnings
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
Best DNA Test for 2024
Newlink Technology Inc.
Newlink Technology Inc (9600)
See More Headlines

NLNK Stock Analysis - Frequently Asked Questions

NewLink Genetics Corp (NASDAQ:NLNK) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative trailing twelve-month return on equity of 41.50% and a negative net margin of 4,592.84%.

Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Bristol Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Gilead Sciences (GILD), CSLM Acquisition (SPWR) and Sarepta Therapeutics (SRPT).

Company Calendar

Last Earnings
11/06/2019
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NLNK
CIK
1126234
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.99 million
Net Margins
-4,592.84%
Pretax Margin
N/A
Return on Equity
-41.50%
Return on Assets
-33.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.98
Quick Ratio
7.98

Sales & Book Value

Annual Sales
$940 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.11 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
37,328,000
Free Float
N/A
Market Cap
$162.00 million
Optionable
Not Optionable
Beta
1.17
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:NLNK) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners